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Abstract
Background: Polypoidal choroidal vasculopathy is a variant of choroidal neovascularization and neovascular age
related macular degeneration presenting with hemorrhagic and exudative changes within the macula and/or
peripapillary region leading to vision loss. In contrast to neovascular age related macular degeneration, polypoidal
choroidal vasculopathy has differing clinical manifestations and treatment strategies. Historically, polypoidal
choroidal vasculopathy complexes are less responsive to anti-vascular endothelial growth factor therapy with no
prospective clinical trials evaluating aflibercept in management of polypoidal choroidal vasculopathy. Herein we
prospectively evaluate the efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy.
Methods: A prospective, open-label, investigator-sponsored trial of intravitreal aflibercept for polypoidal choroidal
vasculopathy in 21 eyes was conducted. Injections were administered monthly for 3 initial treatments, then every
other month with monthly evaluations. The primary outcome measures were the mean change in best corrected
visual acuity and adverse events. Secondary outcome measures included stabilization of vision, presence of
subretinal hemorrhage, serous detachment, retinal pigment epithelial detachment, and regression of
polypoidal complexes on indocyanine green angiography.
Results: At 6 months, the median visual acuity was 20/40 (range 20/25–20/200) with a mean Early Treatment
Diabetic Retinopathy Study vision of 68.4 letters. There was a gain of 2.76 Early Treatment Diabetic Retinopathy Study
letters at 6 months (p = 0.15). No patient developed severe vision loss (≤15 letters) and vision was stable or improved
in 19/21 eyes (91 %). Subretinal fluid resolved in 13/18 eyes (72 %), and subretinal hemorrhage resolved in 6/8 eyes
(75 %) respectively. The polyps regressed in 14/21 eyes (67 %) and the branching vascular network decreased in 1 eye
and was stable in all other eyes. The retinal pigment epithelial detachment improved in 13/15 eyes (87 %). Bimonthly
treatment occurred in 15/21 patients (71 %). There were no adverse events.
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Conclusions: Intravitreal aflibercept results in stabilization of vision, resolution of exudative and hemorrhagic
complications with regression of polyps in polypoidal choroidal vasculopathy. Eyes with polypoidal choroidal
vasculopathy previously treated with ranibizumab and bevacizumab can show marked improvement in the retinal
pigment epithelial detachments and persistent polyps with aflibercept therapy.
Trial registration: Clinical trials.gov NCT01871376, June 4th 2013
Keywords: Choroidal neovascularization, Polypoidal choroidal vasculopathy, Aflibercept, Exudative macular
degeneration, Retinal pigment epithelial detachment
Background
Polypoidal choroidal vasculopathy (PCV) is increasingly
recognized as a cause of exudative and hemorrhagic
complications in the macula [1–3]. Patients with PCV
present with subretinal hemorrhage, subretinal fluid, and
retinal pigment epithelial detachment (RPED). These
findings are associated with a subretinal branching vas-
cular network (BVN) with characteristic “polyplike”
structures at the terminal ends of the vessels [1–5].
Since many of the fundus and optical coherence tomog-
raphy (OCT) findings are similar to typical exudative
age related macular degeneration (AMD), indocyanine
green (ICG) angiography is essential to diagnosing PCV
[1, 5]. Polypoidal choroidal vasculopathy is a variant of
type I subretinal neovascularization (Gass classification)
[6], in which the neovascular complex grows beneath
the retinal pigment epithelium (RPE) and above Bruch’s
membrane [7–9].
The treatment of the hemorrhagic and exudative
complications of PCV is not well defined, but thera-
peutic approaches include photodynamic therapy
(PDT), anti-vascular endothelial growth factor (VEGF)
therapy, combined PDT and anti-VEGF therapy, direct
thermal laser to polyps, and surgical management of
significant subretinal hemorrhage or hemorrhagic ret-
inal detachment [10]. Photodynamic therapy has been
the mainstay of treatment in Asia for years [11–14],
and was supported by an expert panel on PDT man-
agement in Asia. This treatment is usually guided by
the size of the complex on ICG angiography. [11].
Polypoidal choroidal vasculopathy is much more com-
mon in Asian populations and is being increasingly
recognized in White populations with more frequent
use of ICG angiography [3, 15–20].
Anti-VEGF therapy has recently been shown to be ef-
fective in decreasing the exudation, macular edema, and
hemorrhage associated with PCV [12, 21–25]. Although
retrospective studies are numerous, there are very
limited prospective studies available for evaluation of the
different anti-VEGF agents. For ranibizumab treatment
in PCV, there are 6 month prospective results available
in the Efficacy and safety of verteporfin photodynamic
therapy in combination with ranibizumab or alone
versus ranibizumab monotherapy in patients with symp-
tomatic macular polypoidal choroidal vasculopathy trial
(EVEREST trial ranibizumab 0.5 mg) [12], in the investi-
gator sponsored trial for Polypoidal Choroidal Vasculop-
athy with Intravitreal Ranibizumab (PEARL trial,
ranibizumab 0.5 mg) [21, 23], and in the investigator
sponsored trial of Polypoidal Choroidal Vasculopathy
Evaluation Assessing High-Dose Ranibizumab Prospect-
ively (PEARL2 trial, 2.0 mg ranibizumab) [8]. For afliber-
cept, only one recent prospective study of aflibercept
2.0 mg exists in treatment naïve eyes with exudative or
hemorrhagic PCV [22]. The Prospective Clinical Trial of
Intravitreal Aflibercept Treatment for PolypoIdal Chor-
oidal Vasculopathy with Hemorrhage or Exudation trial
(EPIC trial) results reported herein provides 6 month re-
sults on eyes with PCV that were both treatment naïve,
as well as eyes previously treated with anti-angiogenic
therapy, including treatment with high dose ranibizumab
therapy (ranibizumab 1.0 mg or 2.0 mg) for 24 months
in the PEARL2 trial.
Methods
The EPIC trial (Intravitreal Aflibercept Injections
(Eylea®) for Polypoidal Choroidal Vasculopathy with
Hemorrhage or Exudation) is an ongoing, prospective,
open-label clinical trial of intravitreal aflibercept
(2.0 mg/0.05 mL) in patients with active hemorrhage, ex-
udation, or recent decrease in vision (defined as a loss of
five Early Treatment Diabetic Retinopathy Study letters
(ETDRS) or one Snellen line of vision in the past
6 months) associated with PCV. Major exclusion criteria
include: (1) history of previous vitrectomy; (2) previous
cataract surgery within 2 months prior to the baseline
visit; (3) presence of any condition that would jeopardize
the patient’s participation in this study; (4) no prior anti-
VEGF (pegaptanib, bevacizumab, ranibizumab, afliber-
cept) in study eye within 30 days of enrollment; (5)
known allergy to the study drug; (6) poorly controlled
hypertension; (7) major surgery within 28 days prior to
study. The EPIC study was approved by the Western
Institutional Review Board (IRB, Puyallup, Washington,
Study Number 1138211) and listed on clinical trials.gov
(NCT01871376). The study was carried out at The
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Retina Center at Pali Momi. It adhered to the tenets
of the guidelines of the Declaration of Helsinki, and
each patient completed a written informed consent.
The EPIC trial also followed the TREND guidelines/
methodology. This study was supported in part as an
investigator-sponsored trial by a research grant from
Regeneron, Inc (Tarrytown, New York). The investiga-
tors maintained complete control of the data and its
interpretation.
The clinical diagnosis of PCV was based on fundu-
scopic identification of serous retinal detachment, macu-
lar edema, subretinal hemorrhage, or RPED. The
definitive diagnosis was confirmed by ICG angiography,
in which PCV complexes were identified as polyps with
or without a BVN (Fig. 1). All patients received multiple,
open-label intravitreal injections of 2.0 mg aflibercept
(Regeneron, Tarrytown, New York, United States)
administered per protocol for 6 months. The first 3
months required monthly mandatory dosing (30 days +
7 days) (baseline, month 1, month 2). Subsequent injec-
tions were administered every other month (60 days ±
7 days). If needed, patients were allowed monthly
treatment (30 days ± 7 days), if there was recurrence or
persistence of subretinal fluid, subretinal hemorrhage or
macular edema with or without vision loss. Recurrence
of subretinal fluid or hemorrhage after previous reso-
lution of subretinal fluid or hemorrhage required three
consecutive monthly mandatory injections before a pos-
sible monthly examination without treatment could be
considered.
At baseline all patients had a complete ophthalmic
examination with best corrected visual acuity deter-
mined with ETDRS charts and refraction at 4 m
(BCVA), slit-lamp examination, funduscopic biomicro-
scopic examination, fundus photography, fundus auto-
fluorescence testing, fluorescein angiography (FA), and
ICG angiography using the scanning laser ophthalmo-
scope (Heidelberg Spectralis HRA +OCT, Heidelberg
Engineering USA, Carlsbad, California) and optical
coherence tomography (OCT) with point-to-point
localization of the OCT with the FA and ICG angiog-
raphy landmarks. Ophthalmic examination, visual acuity,
fundus autofluorescence (FAF), and OCT were per-
formed monthly. Early Treatment Diabetic Retinopathy
Fig. 1 Marked reduction of treatment-naïve polyp after 6 months of intravitreal aflibercept. a. EPIC study baseline ICG angiogram (left) with
correlated OCT study (right). Note the hyperfluorescent polyp with hypofluorescent ring on ICG angiogram. On the OCT, an inverted U-shaped polyp
(arrow) is seen with surrounding serous detachment. b. ICG angiogram (left) following 6 months of intravitreal aflibercept with corresponding OCT
(right) reveals marked reduction in the polyp (arrow)
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Study vision at 4 m, FA, and ICG angiography were per-
formed at baseline, and at 1,3, and 6 months. Eyes will
be followed in the study for 24 months.
The primary outcome measures are the mean change
in BCVA and the incidence and severity of ocular and
systemic adverse events. Secondary outcome measures
included stabilization of vision (loss of <15 ETDRS let-
ters), changes in subretinal fluid, presence of subretinal
hemorrhage, decrease in RPED, change in central foveal
thickness (CFT), presence of macular edema, leakage on
fluorescein angiography, and regression of polypoidal
complexes on ICG angiography. The PCV complex was
composed of polyp lesions and a BVN in all patients.
Both components were evaluated separately. Decrease in
polyp lesion or BVN was any decrease in size or number
of polyps as compared to baseline imaging. Stable find-
ings of the polyp or BVN indicates no change in size or
number of polyps in response to therapy. Regression
and/or resolution of the polyp indicates that it has re-
solved on ICG. Macular edema was defined as an in-
crease in macular thickness including subretinal fluid
and intraretinal edema as visualized on OCT. Paired t-
tests were performed to compare baseline and 6 month
ETDRS best corrected visual acuity and change in OCT
CFT. Statistical significance was based on p values <0.05
and the statistical analysis was performed using SAS 9.2
software (Cary, North Carolina).
Results
Baseline characteristics of patients entered into the EPIC
trial can be found in Table 1. Patients were treated with
bevacizumab and/or ranibizumab with a range of 1 to 36
injections in the 11 patients previously treated with anti-
VEGF therapy. Before entering the EPIC trial, patients
did not receive an injection within 30 days of screening
and had active disease at entry. The one patient with
prior PDT had two PDT treatments over 2 years before
entering the EPIC trial and had developed recurrent
leakage and serous detachment upon entry. All patients
with active leakage or bleeding associated with PCV
were offered entry into the EPIC trial.. Baseline findings
included subretinal fluid in 18/21 eyes (86), subretinal/
sub-RPE hemorrhage in 8/21 eyes (38), and RPED in 15/
21 eyes (71 %). On ICG angiography polypoidal com-
plexes were in the macula in 17 eyes (81), in the peripa-
pillary region alone in 1 eye (5), and in both the macular
and peripapillary regions in 3 eyes (14 %) at the baseline
EPIC study visit. The median BCVA was 20/40 (range:
20/16 – 20/200) at baseline and 20/40 (range: 20/25 –
20/200) at 6 months. The BCVA was 20/32 or better at
baseline in 11/21 eyes (52 %). The range of vision in the
remaining 10 eyes was from 20/40 to 20/200. The mean
ETDRS BCVA was 65.7 letters at baseline, and 68.4 let-
ters at 6 months (Table 2). The average gain in ETDRS
letters over 6 months was 2.76 letters (p = 0.15). None of
the patients lost ≥ 15 letters in ETDRS vision at
6 months. One patient (5 %) gained ≥ 15 letters at
6 months (Fig. 2). Six eyes (29) improved ≥ 5 letters, thir-
teen eyes (61) remained unchanged (<5 letter change)
from baseline, and two eyes (10 %) decreased ≥ 5 letters.
The changes in ETDRS letters based on previous treat-
ment can be found in Table 3.
At 6 months, subretinal hemorrhage resolved in 6/8
eyes (75), persisted in 1/8 eyes (12.5), and increased in
1/8 eyes (12.5 %). Subretinal fluid completely resolved in
13/18 eyes (72 %), decreased in 3/18 eyes (17 %), and
remained stable in 2/18 eyes (11 %). A statistical signifi-
cant decrease was noted in the comparison of the aver-
age CFT at baseline (282 μm) and at 6 months (207 μm)
with an average decrease of 75 μm (p = 0.0014, Table 2).
The RPED resolved completely or decreased in 13/15
eyes (87 %) (Fig. 3), stable in 1/15 eyes (7 %), and in-
creased in 1/15 eyes (7 %). Significant macular edema at
baseline due to PCV was present in 17/21 eyes (81 %).
In these 17 eyes, macular edema improved in 13/17 eyes
(76 %). In 4 cases, the edema remained stable.
At 6 months 15/21 eyes (71 %) received treatment
every other month per EPIC protocol. The remaining 6
eyes (29 %) were receiving monthly injections at month
6. This included 3 eyes with 6 monthly injections, and 3
eyes with 5 injections. Two patients had recurrences
both occurring at month 4. These recurrences then ne-
cessitated restarting monthly therapy for 3 aflibercept
treatments. One patient missed a follow-up evaluation at
Table 1 Baseline Characteristics of the EPIC Study
Characteristic (N = 21)
Mean Age, Years (Range) 77 (59 – 91)







Prior Treatment, N (%)
Prior Anti-VEGF 11 (52)
Prior ML 1 (4)
Prior PDT 1 (4)
None (Treatment-Naïve) 10 (48)
Median Visual Acuity (Range) 20/40 (20/200 – 20/16)
Mean ETDRS Letters (Range) 65.7 (30 – 89)
Mean Central Foveal Thickness, (μM) 283 (164 – 550)
VEGF vascular endothelial growth factor, ML macular laser, PDT Photodynamic
therapy, ETDRS Early Treatment Diabetic Retinopathy Study, μm micrometers,
n number
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month 3. This patient had persistent subretinal fluid
throughout the study and required monthly treatment-
s..Of the 15 eyes on every other month treatment at
month 6, only one of the fifteen eyes developed recur-
rent subretinal hemorrhage at the month 6 evaluation.
The other 14 eyes had resolved subretinal fluid and sub-
retinal hemorrhage at month 6 on every other month
therapy.
The response of the polypoidal complex to aflibercept
therapy utilizing the EPIC protocol was evaluated with
ICG angiography (Table 2). Polyps resolved or decreased
in 14/21 eyes (67 %) (Figs. 1, 4). Complete polyp regres-
sion was noted in 6/21 eyes (29 %). Polyps remained
stable in 6/21 (29 %) eyes. In one eye (5 %), there was a
localized increase in the inferior peripheral polyps along
the PCV complex on aflibercept therapy, the BVN
remained stable in size without associated bleeding or
leaking at 6 months. The BVN remained the same size
in 20 eyes (95) and decreased in one eye (5 %). In the 15
eyes presenting with RPED, the ICG angiogram looks
hypofluorescent in the area of the RPED. However, if the
RPED flattens, the polypoidal complex may then show
increased visibility of the BVN (Fig. 3c). This was noted
in 9 of the 15 eyes (60 %) initially presenting with RPED,
where 13 eyes showed significant flattening of the RPED
(Fig. 3 a, b). In one eye that had received 24 months of
high dose ranibizumab in the PEARL2 study, there was
a marked reduction in polyps on aflibercept at 6 months
(Fig. 4).
On fundus autofluorescence at baseline polyps were
seen as hyperauthofluorescent with a surrounding
hypoautofluorescent ring in 9 eyes, hyperautofluorescent
in 3 eyes, hypoautofluorescent in 6 eyes, and hypoauto-
fluorescent with hyperautofluorescent ring in 2 eyes.
The BVN was visualized as hypoautofluorescent in 13
eyes, hyperautofluorescent in 6 eyes and not visualized 2
eyes respectively. At 6 months polyps were not visual-
ized in 10 eyes, hyperautofluorescent in 4 eyes, hypoau-
tofluorescent in 5 eyes, hypoautofluorescent with
hyperautofluorescent ring in 2 eyes. The BVN’s at
6 months were hypoautofluorescent in 14 eyes,, hyperau-
tofluorescent in 3 eyes, and not visualized in 4 eyes. The
BVN’s in these patients had indistinct borders. At base-
line 4 patients had blocked autofluorescence due to SRH
which resolved in 3 patients at 6 months. In 4 patients
there were areas of diffuse hyper-autofluorescence
within the macula.
There were no ocular or systemic adverse events noted
in the study at 6 months.
Discussion
Polypoidal choroidal vasculopathy is a major cause of
leaking and bleeding in the macula and may respond dif-
ferently to therapeutic agents than typical exudative
AMD [8, 9]. In the EPIC study, aflibercept was evaluated
in an IRB-approved, prospective, clinical trial as an
intravitreal therapy for PCV in eyes with confirmation of
the PCV diagnosis by ICG angiography. Significant reso-
lution of leaking and bleeding was noted in response to
aflibercept. A statistical significant decrease in CFT was
observed in these subset of patients. In addition, signifi-
cant reduction was noted in RPED in 87 % of cases
(Fig. 3). In the PEARL study (ranibizumab 0.5 mg) there
was a 50 % reduction in RPED [21], and in the PEARL2
study (2.0 mg ranibizumab) there was a 63 % reduction
in RPED [8]. In one patient entering the EPIC study
there was a persistent large RPED after 24 monthly high
dose ranibizumab injections in the PEARL2 study. After
entering the EPIC trial with aflibercept, the highly ele-
vated vascularized RPED resolved at 3 months and
remained flat at month 6 with maintenance of stable
vision (Fig. 3a). A greater resolution of RPED has also
been noted after switching from bevacizumab and rani-
bizumab to aflibercept in multiple studies on therapy for
wet AMD [26, 27]. ICG angiography was not performed
in these studies, but vascularized RPED is more frequent
Table 2 Comparisons of change in clinical manifestations at



















1 71 70 210 199 = =
2 30 60 176 119 ↓ =
3 72 68 230 235 R =
4 75 73 398 177 = =
5 48 49 276 218 ↓ =
6 75 68 318 188 = =
7 58 72 278 289 = =
8 59 68 352 343 = =
9 74 83 237 227 R =
10 82 80 550 198 ↓ ↓
11 80 81 249 183 R =
12 38 37 208 193 ↓ =
13 60 67 317 227 R =
14 36 38 387 163 ↓ =
15 83 80 223 200 = =
16 73 77 222 221 ↑ =
17 74 76 346 220 R =
18 89 83 196 178 ↓ =
19 74 73 290 223 ↓ =
20 61 70 315 190 ↓ =
21 67 64 164 158 R =
CFT Central foveal thickness, ETDRS: Early Treatment Diabetic Retinopathy
Study, BVN: Branching vascular network, ICG: Indocyanine green angiography,
↑ = increased, ↓ = decreased, = =stable, R regressed
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in eyes with PCV than in eyes with typical exudative
AMD.
Previous studies have demonstrated a higher rate of
polyp regression in therapies utilizing PDT, or combin-
ation PDT and intravitreal injection of antiangiogenic
drug. In the EVEREST study at 6 months there was a
77.8 % polyp closure rate with PDT + ranibizumab, a
71.4 % polyp closure rate with PDT alone, and a 28.6 %
polyp closure rate with ranibizumab monotherapy [12].
However, there was not a statistically significant differ-
ence in vision results. The PEARL trial confirmed a rela-
tively low rate of polyp regression of 33 % at 6 months
[21], and 38 % after one year of monthly 0.5 mg ranibi-
zumab therapy [23]. The PEARL, PEARL2 and EPIC
studies are different prospective trials with different
agents and different patient populations with relatively
small sample sizes, so comparison between studies can-
not be directly made. However, the ETDRS vision test-
ing, OCT evaluation, and ICG angiography evaluations
were consistent across all 3 studies. The anatomic data
does show a higher polyp regression rate in the EPIC
study of 67 %. In the PEARL study, the polyp regression
rate was 33 % at 6 months [21] and in the PEARL2 study
the polyp regression rate was 63 % at 6 months [8], but
this dose is not commercially available. In one patient
previously treated with high dose ranibizumab in the
PEARL2 study, there were marked persistent polyps,
which markedly regressed after 6 months of treatment
with aflibercept in this EPIC study (Fig. 4).
Because half of the eyes entering into the EPIC study
had a BCVAof 20/32 or better, a significant improve-
ment in vision (>15 letters) could not be demonstrated
in these eyes due to the ceiling effect. There was not a
statistically significant improvement in mean BCVA in
this patient population with good baseline vision, but
the primary endpoint for vision showed that none of the
Table 3 Comparison of change in ETDRS from baseline
6 months of treatment in the EPIC trial





Improved≥ 5 Letters 3 (30) 3 (27) 6
Unchanged < 5 Letters
Change
6 (60) 7 (64) 13
Decreased≥ 5 Letters 1 (10) 1 (9) 2
Increase≥ 15 Letters 0 0 0
Decrease≥ 15 Letters 0 1 (9) 1
ETDRS Early Treatment Diabetic Retinopathy Study
Fig. 2 ICG angiogram with correlated OCT study in a previously treated eye in the PEARL 2 Study (12 2.0 mg ranibizumab + 12 1.0 mg
ranibizumab) with additional bevacizumab intravitreal injections prior to entry into the EPIC study. a. Baseline EPIC Study images. ICG
angiogram shows hypofluorescence (see arrowhead) in the area of the subretinal hyperreflective material and the central RPED. OCT
shows a central RPED (arrow) with nasal subretinal hyperreflective material (asterisk). b. EPIC Month 6 imaging. ICG angiogram shows
decrease in the area of hypofluorescence. OCT shows resolution of the subretinal hyperreflective material and decrease in the RPED.
Visual acuity improved from 20/160 to 20/63 (+30 letters)
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patients developed severe vision loss (>15 letters). The
great majority of eyes showed stability of vision with
90 % showing no loss of vision of greater than 5 ETDRS
letters after 6 months.
PCV tends to have a higher incidence of anti-VEGF
resistance [19], but in the EPIC study 71 % of eyes were
able to be treated with every other month therapy at
month 6 after the initial 3 monthly aflibercept treat-
ments. Only one of these eyes developed recurrence at
month 6, and then required monthly therapy. In one
case treated in the PEARL2 study after 24 months of
monthly high dose ranibizumab therapy there was
marked resolution of persistent polyps on therapy with
aflibercept (Fig. 4). This high rate of polyp closure with
aflibercept was confirmed in the recent study by
Hosokawa and colleagues with a 77.7 % resolution rate
of polyps [22]. In another patient that was previously
treated with ranibizumab in the PEARL2 Study and
Fig. 3 Resolution of a vascularized RPED after aflibercept therapy. a. An Asian male with a persistent large vascularized RPED after
24 months of high dose ranibizumab therapy (12 2.0 mg ranibizumab + 12 1.0 mg ranibizumab injections) in PEARL2 study at EPIC
baseline (upper left). Resolution of the vascularized RPED which initially resolved at month 3 and stayed resolved at month 6 (upper
right) b. Treatment naïve Caucasian female with vascularized RPED at EPIC baseline (left) and after aflibercept therapy at month 6 (right).
Note the marked improvement in the vascularized RPED. c. Corresponding ICG angiogram to patient in B. Increased visibility of BVN after
RPED resolution on aflibercept therapy. ICG angiogram shows hypofluorescence in the area of the RPED at baseline with inferior PCV
complex (left). Follow-up ICG angiogram shows decreased hypofluorescence due to resolution of the RPED. Note the increased visibility
of the hyperfluorescent BVN (right)
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intravitreal bevacizumab, a persistent RPED with hyper-
reflective material was noted prior to entry into the
EPIC trial. After treatment with aflibercept the central
RPED decreased with resolution of the subretinal hyper-
reflective material and BCVA improvement from 20/160
to 20/63. This patient had a better anatomical and visual
acuity response to aflibercept therapy than the previous
anti-VEGF therapies highlighting the use of aflibercept
in PCV patients that may not respond completely to
other agents (Fig. 2).
Fundus autofluorescence was performed in all patients.
At baseline there was more abnormalities as previously
described by Koizumi as hyperautofluorescent lesions
with a hypoautofluorescent ring, but this was less notice-
able after treatment. This technique of imaging
produced varied results of the characteristic polyps and
BVN’s when compared to ICG. The BVN in all patients
had indistinct borders making it difficult to distinguish
lesion extent. In select patients areas of diffuse hyper-
autofluorescence were noted corresponding to areas of
previous leakage with RPE stress [28].
While this study was designed as a prospective, open-
label, clinical trial there are still limitations present. One
is the small sample size, in which larger prospective clin-
ical trials with treatment of PCV are necessary to further
define and validate the appropriate treatment algorithms.
This study included patients that have been previously
treated with PDT and/or anti-VEGF therapy which
might negate responses to the current therapy. Lastly,
the initial visual acuity criteria being very good at entry
Fig. 4 Resolution of polyps on aflibercept in an Asian Male with a large vascular PCV complex persisting after 24 months of high dose
ranibizumab therapy (PEARL2, 6 2.0 mg ranibizumab + 18 1.0 mg ranibizumab injections). a. EPIC baseline ICG angiogram showing persistent
polyps (circles). b-d. EPIC baseline images with ICG angiogram and corresponding polyps (arrows) on OCT. e. Epic month 6 ICG angiogram
showing marked polyp resolution. f-h. EPIC month 6 ICG angiogram with corresponding OCT images displaying significant polyp (arrows)
reduction on aflibercept therapy
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led to the inability to detect a statistical significant
change in vision after treatment due to the ceiling effect.
The EPIC results are promising for the treatment of
PCV in resolution of the leaking and bleeding complica-
tions of PCV, as well as in regards to increased reso-
lution of the PCV complex. In addition, duration of
therapy may allow less frequent dosing, as 71 % of cases
were treated with every other month therapy by month
6. Possible etiologies for this increased effect in PCV are
the higher binding affinity of aflibercept, as well as pos-
sible active transport of the aflibercept molecule across
the RPE cells. As shown in pre-clinical studies, ranibizu-
mab depends on a gradient diffusion between RPE cells,
whereas aflibercept is actively transported to the sub-
retinal pigment epithelial space by RPE cells [29].
Conclusion
Intravitreal aflibercept therapy is an effective treatment
in PCV. It can stabilize vision, resolve exudative and
hemorrhagic complications in the macula, and promote
polyp regression within the PCV complex.. Future stud-
ies with longer term results and larger numbers of pa-
tients will help to further guide aflibercept’s role in PCV
management.
Additional file
Additional file 1: Epic 6 Month Results. The data in this supplementary
table consists of both descriptive anatomical descriptions and
quantitative data that was used to determine the effect aflibercept
therapy had on the hemorrhagic and exudative changes within the
macula. (XLS 107 kb)
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